| Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis (NCT05590247) | Ohio State University | 2022-07-21 |
| A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis (NCT05453942) | Sanofi | 2022-07-12 |
| Tunisian National Registry on Psoriasis (NCT05258838) | Dacima Consulting | 2022-07-12 |
| Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis (NCT05399433) | Centre Hospitalier Universitaire de Nice | 2022-06-30 |
| Monitoring of Inflammatory Conditions (NCT05458531) | University of Nottingham | 2022-06-28 |
| Asking People With Psoriasis About Lifestyle and Eating (NCT05448352) | King's College London | 2022-06-18 |
| Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases (NCT05406908) | Mahidol University | 2022-06-15 |
| Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects (NCT04711343) | Bio-Thera Solutions | 2022-06-08 |
| Biofeedback for Psoriasis (NCT05506644) | Bastyr University | 2022-06-07 |
| The Disease Severity In Patients With Psoriasis (NCT05943405) | Universitas Sebelas Maret | 2022-06-01 |
| Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis. (NCT05311501) | University of Siena | 2022-05-10 |
| JAK-STAT Signaling Pathway in Pyoderma Gangrenosum (NCT04792957) | Dokuz Eylul University | 2022-05-01 |
| Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors (NCT04751396) | M.D. Anderson Cancer Center | 2022-04-20 |
| Effects of Tildrakizumab on Epigenetic Age (NCT05110313) | Carlos Wambier | 2022-04-08 |
| Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis (NCT05326659) | Peking University People's Hospital | 2022-04-01 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% (NCT05461456) | OrchestratePharma GmbH | 2022-04-01 |
| Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques (NCT05642182) | SFA Therapeutics | 2022-03-31 |
| Phase I Study of GN-037 Cream for Psoriasis (NCT05428202) | TC Erciyes University | 2022-03-28 |
| Excimer Light in Psoriasis (NCT05283876) | Cairo University | 2022-03-10 |
| Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis (NCT06043752) | Ghurki Trust and Teaching Hospital | 2022-03-10 |
| Safety and Tolerability Study of MSC Exosome Ointment (NCT05523011) | Paracrine Therapeutics Dermatology Pte. Ltd. | 2022-03-08 |
| Efficacy and Safety of Apremilast in Psoriasis (NCT06032858) | Ghurki Trust and Teaching Hospital | 2022-03-06 |
| High Dose Risankizumab for Psoriasis (NCT05283135) | Oregon Medical Research Center | 2022-03-01 |
| Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis. (NCT05252741) | Sohag University | 2022-02-20 |
| Multi-Center PAMPA Study (NCT05004727) | NYU Langone Health | 2022-02-16 |
| Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (NCT05185258) | Aarhus University Hospital | 2022-02-16 |
| Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) (NCT04535999) | University of Pennsylvania | 2022-02-07 |
| UVB-induced Treg Cells Exert Antigen-specific Suppression Through LAG-3 (NCT05636839) | National Taiwan University Hospital | 2022-01-25 |
| A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis (NCT04839328) | Tianjin Hemay Pharmaceutical Co., Ltd | 2022-01-20 |
| Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis (NCT05427175) | Aswan University Hospital | 2022-01-10 |
| Subclinical Impairment of Cardiovascular System in Patients With Psoriasis (NCT05957120) | University Medical Centre Ljubljana | 2022-01-03 |
| Psorcast Mobile Study (NCT05621369) | Sage Bionetworks | 2022-01-01 |
| Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis (NCT06555497) | Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium | 2022-01-01 |
| Study to Assess the Efficacy and Safety of Orismilast in Psoriasis (NCT05190419) | UNION therapeutics | 2021-12-30 |
| A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream (NCT05514353) | Pyramid Biosciences | 2021-12-28 |
| Pleiotropic Role of TRPV1 in Psoriasis Inflammation (NCT04848194) | University Hospital, Brest | 2021-12-22 |
| Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis (NCT05111210) | Institut Pasteur | 2021-12-14 |
| Quest to Analyze One Thousand Humans Meditating (NCT06583395) | Tobias Moeller-Bertram | 2021-12-05 |
| A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis (NCT05044234) | AbbVie | 2021-11-16 |
| Validation of a Dermatology-Specific Treatment Satisfaction Instrument (NCT05056168) | University of Southern California | 2021-11-13 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects (NCT06033742) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-11-13 |
| Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines (NCT05144165) | Centre of Evidence of the French Society of Dermatology | 2021-11-08 |
| Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity (NCT05132231) | Bausch Health Americas, Inc. | 2021-10-22 |
| ProspectIve Cohort psoriASiS fOllow-up (PICASSO) (NCT05122039) | Universitaire Ziekenhuizen KU Leuven | 2021-10-20 |
| The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic (NCT05098600) | Faculty Hospital Kralovske Vinohrady | 2021-10-15 |
| Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients (NCT05076812) | Sohag University | 2021-10-01 |
| Topical Methotrexate Microemulsion in the Treatment of Plaque Psoriasis (NCT04971239) | Assiut University | 2021-10-01 |
| Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (NCT05065762) | Bristol-Myers Squibb | 2021-10-01 |
| Cardiovascular Risk Predictors in Patients With Psoriasis (NCT05200598) | I.M. Sechenov First Moscow State Medical University | 2021-10-01 |
| A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (NCT04894890) | Novartis Pharmaceuticals | 2021-09-26 |
| A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis (NCT05003531) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-23 |
| Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis (NCT04841187) | Assistance Publique - Hôpitaux de Paris | 2021-09-06 |
| Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis (NCT04950218) | Herlev and Gentofte Hospital | 2021-09-01 |
| Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis (NCT07169682) | National and Kapodistrian University of Athens | 2021-09-01 |
| Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis (NCT03745417) | Guangdong Provincial Hospital of Traditional Chinese Medicine | 2021-08-31 |
| A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis (NCT04914429) | Janssen Research & Development, LLC | 2021-08-25 |
| Metabolic Profiling of Immune Responses in Immune-mediated Diseases (NCT04864886) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-10 |
| Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging (NCT05135312) | OptiSkin Medical | 2021-08-09 |
| MBCT for Psoriasis Patients With Anxiety and Depression (NCT05010044) | First Affiliated Hospital Xi'an Jiaotong University | 2021-08-01 |
| Subjects Through the Application of the Mindera Kit Part 2 (NCT04904315) | Mindera Health | 2021-08-01 |
| A Study of LY3361237 in Participants With Psoriasis (NCT04975295) | Eli Lilly and Company | 2021-07-27 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (NCT04862286) | AbbVie | 2021-07-24 |
| A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis (NCT04967508) | Samsung Bioepis Co., Ltd. | 2021-07-06 |
| A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors (NCT04776629) | Abcentra | 2021-06-30 |
| Brain Changes in Psoriasis After Secukinumab Treatment (NCT04717466) | University of Miami | 2021-06-29 |
| A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan (NCT04826536) | Bristol-Myers Squibb | 2021-06-25 |
| Anti-Inflammatory Effects of Time-Restricted Feeding (NCT04728165) | National Heart, Lung, and Blood Institute (NHLBI) | 2021-06-09 |
| Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy (NCT04908475) | AbbVie | 2021-06-09 |
| Effect of Chronic Inflammation on Myocardial Perfusion and Function (NCT04870827) | National Heart, Lung, and Blood Institute (NHLBI) | 2021-06-07 |
| Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients . (NCT05401006) | South Valley University | 2021-06-05 |
| Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis (NCT04930042) | Alvotech Swiss AG | 2021-06-03 |
| Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults (NCT05064748) | Peking University People's Hospital | 2021-06-01 |
| Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan (NCT04818385) | AbbVie | 2021-05-31 |
| Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) (NCT04744363) | Alvotech Swiss AG | 2021-05-25 |
| Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects (NCT04837235) | Tianjin Hemay Pharmaceutical Co., Ltd | 2021-04-29 |
| Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care (NCT04780516) | AbbVie | 2021-04-26 |
| Risankizumab Long-term Remission Study (NCT04630652) | Jaehwan Kim | 2021-04-07 |
| A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (NCT05604898) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-04-01 |
| Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Diseases. (NCT05125458) | University of Campania Luigi Vanvitelli | 2021-04-01 |
| SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE (NCT04417114) | Brigham and Women's Hospital | 2021-04-01 |
| Shortening Treatments Of Chronic Inflammatory Conditions (NCT04848649) | Centre Hospitalier Universitaire de Besancon | 2021-04-01 |
| Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults (NCT04843631) | BioFactura Australia Pty Ltd. | 2021-04-01 |
| A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis (NCT03988439) | Bausch Health Americas, Inc. | 2021-03-24 |
| A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT04761627) | Amgen | 2021-03-24 |
| Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis (NCT05513014) | Novartis Pharmaceuticals | 2021-03-21 |
| Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis (NCT04785027) | Guangdong Provincial Hospital of Traditional Chinese Medicine | 2021-03-17 |
| The Diagnostic Ultrasound Enthesitis Tool (DUET) Study (NCT04587362) | Women's College Hospital | 2021-03-17 |
| Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis (NCT07707141) | Newsoara Biopharma Co., Ltd. | 2021-03-03 |
| Iontophoresis in Psoriasis (NCT03979664) | Wake Forest University Health Sciences | 2021-03-01 |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) (NCT04746911) | Arcutis Biotherapeutics, Inc. | 2021-03-01 |
| Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (NCT04713592) | AbbVie | 2021-02-26 |
| Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma (NCT04927195) | Evelo Biosciences, Inc. | 2021-02-23 |
| Non-invasive Photoacoustic Imaging of Skin Inflammatory Disorders With Machine Learning-assisted Scoring (NCT04809571) | Institute of Bioengineering and Bioimaging (IBB) | 2021-02-22 |
| Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab) (NCT05320159) | Novartis Pharmaceuticals | 2021-02-03 |
| Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis (NCT04693936) | University of Crete | 2021-02-02 |
| Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis (NCT04423471) | Germans Trias i Pujol Hospital | 2021-02-01 |
| Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity (NCT04722640) | Istituto Clinico Humanitas | 2021-01-25 |
| Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study (NCT04722094) | University of Siena | 2021-01-25 |
| Rimegepant in Moderate Plaque-type Psoriasis (NCT04629950) | Weill Medical College of Cornell University | 2021-01-19 |
| A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis (NCT04673786) | Celltrion | 2021-01-11 |